Showing results (321-330 of 2,733) with videos related to
Sort By:
Pageof 274
Pharmacogenomics|November 3, 2011
Polymorphisms, hypertension and thiazide diureticsLorena Citterio, Chiara Lanzani, Paolo ManuntaPharmacogenomics|October 27, 2011
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapyElisa Giovannetti, Paola Pacetti, Michele Reni, et al.Pharmacogenomics|October 27, 2011
Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adultsSilke Hartleb, Ursula Plöckinger, Günter K Stalla, et al.Pharmacogenomics|October 20, 2011
Pharmacogenomic characterization of US FDA-approved cytotoxic drugsEric J Peters, Alison Motsinger-Reif, Tammy M Havener, et al.Pharmacogenomics|October 20, 2011
Pharmacogenomics and epilepsy: the road aheadGianpiero L Cavalleri, Mark McCormack, Saud Alhusaini, et al.Pharmacogenomics|October 20, 2011
Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseasesLisa K Stamp, Rebecca L RobertsPharmacogenomics|October 20, 2011
The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatmentKerry Reed, Amadeo M ParissentiPharmacogenomics|September 10, 2011
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patientsChin-Chuan Hung, Mu-Han Chiou, Bo-Hau Huang, et al.Pharmacogenomics|September 10, 2011
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patientsChia-Hui Chen, Sheng-Chang Wang, Hsiao-Hui Tsou, et al.Pharmacogenomics|September 17, 2011
Four decades of modern pharmacogenomics: from promise to clinical utility. World PGX Summit 2011. Boston, USA, 26-27 April, 2011Peter Ma GroenenPageof 274